Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Income from Continuing Operations (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Income from Continuing Operations for 10 consecutive years, with 128556000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 4.21% to 128556000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 575000000.0, a 0.88% decrease, with the full-year FY2025 number at 575000000.0, down 0.88% from a year prior.
  • Income from Continuing Operations was 128556000.0 for Q4 2025 at Ultragenyx Pharmaceutical, up from 180413000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 72998000.0 in Q3 2021 to a low of 245106000.0 in Q3 2022.
  • A 5-year average of 145788950.0 and a median of 143610500.0 in 2021 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: crashed 583.62% in 2021, then skyrocketed 34.87% in 2023.
  • Ultragenyx Pharmaceutical's Income from Continuing Operations stood at 124791000.0 in 2021, then decreased by 21.67% to 151833000.0 in 2022, then increased by 18.63% to 123551000.0 in 2023, then decreased by 8.62% to 134202000.0 in 2024, then rose by 4.21% to 128556000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Income from Continuing Operations are 128556000.0 (Q4 2025), 180413000.0 (Q3 2025), and 114951000.0 (Q2 2025).